Navigation Links
The University of Sydney and ResMed partner to accelerate research in sleep-disordered breathing and biomedical engineering
Date:5/13/2013

SYDNEY, May 13, 2013 /PRNewswire/ -- The University of Sydney and ResMed Limited today announced a new partnership that includes significant and long-term funding of research at the University, ultimately benefitting the hundreds of millions of sufferers of sleep-disordered breathing worldwide.

(Logo: http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

(Logo: http://photos.prnewswire.com/prnh/20130513/LA12842LOGO)

Under an agreement recently reached between the parties, ResMed Limited will pay $AU25 million to the University to support its work, including the establishment of two perpetual academic chairs called the ResMed Chair of Sleep Medicine for sleep-disordered breathing with a focus on chronic disease and the ResMed Chair of Biomedical Engineering with an emphasis on bioinformatics research, as well as funding for research in related areas. The agreement also provides for the settlement of proceedings between the parties in the Australian Federal Court regarding a dispute over an earlier licensing agreement.

"Sleep-disordered breathing is a global health problem affecting one in five adults, with broad and deep implications in other chronic conditions, such as hypertension and heart failure," said ResMed Chief Executive Officer Michael Farrell . "With this partnership, we look forward to the University's research revealing new information on how to battle this costly and life-threatening condition."

ResMed is an innovator and pioneer in developing products for the treatment of sleep-disordered breathing and respiratory conditions including COPD. The company's Sydney campus is a manufacturing and innovation centre and headquarters for its Asia-Pacific operations and it employs more than 1,200 people locally.

The University's Vice-Chancellor, Dr Michael Spence expressed his appreciation to ResMed for such a positive contribution and said this agreement "would allow the University to further develop its path-finding research in these critically important areas, as well as provide future opportunities for our researchers."

The University of Sydney's Medical and Health Sciences Research Program is world-class, as evidenced in the 2012 Excellence in Research for Australia report which rated this program "well above world standard."

About ResMed:
ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.Contacts:Gretchen Griswold 

Sarah StockResMed

The University of SydneyDirector, Global Corporate Communications

Head of Media and CommunicationsO: +1 858-836-6789

Ph +61 2 9114 0748 / +61 419 278 715news@resmed.com 

sarah.stock@sydney.edu.au 


'/>"/>
SOURCE ResMed Limited
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Duke University Medical Center Study Finds Prodigy Blood Glucose Monitor System Ranks Highest In Quality Among Leading Brands
2. SonaCare Medical Partners with University College London to Create Center of Excellence for HIFU Surgical Ablation Technology
3. SonaCare Medical to Integrate SmartTarget Image Registration and Fusion Software from University College London into Industry Leading Prostate HIFU System
4. Rush University Medical Center Presents Positive MuGard Clinical Data at the Oncology Nursing Society 38th Annual Congress
5. Cardinal Health Foundation, The Ohio State University Launch Fourth Toolkit to Help Reduce Abuse of Prescription Drugs on College Campuses
6. One-Time, One Dose Radiation Treatment Offered For Breast Cancer Patients At MedStar Georgetown University Hospital And MedStar Washington Hospital Center
7. Walgreens Selects Webster University as Education Provider
8. New Autism Detection System Commercialized through Partnership of IP Shakti, LLC and Shizuoka University
9. Fuisz llc Announces Induction of Richard C. Fuisz, M.D., into Georgetown Universitys 1789 Society.
10. Millennium Research Group Sponsors Case Competition at Western University for Second Year
11. Denmarks Odense University Hospital Orders Elektas New Versa HD Linear Accelerator for Radiotherapy Treatment of Patients with Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017  DarioHealth ... and big data solutions, today announced that its MyDario product is expected ... local TV listings for when The Dr. Oz Show airs in your ... The nine-time Emmy ... ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & Wellness ... Moonlight to raise money for the American Heart Association Heart Walk. Teams of up ... work together to keep their treadmills moving for 5 hours. Treadmills will start at ...
(Date:10/12/2017)... ... 2017 , ... Vohra Chief Medical Officer Dr. Shark Bird, ... nursing facility medical directors and other clinicians at various events in October. His ... many of these conferences we get to educate other physicians, facility nurses, corporate ...
Breaking Medicine News(10 mins):